Wikipedia

Elcin Barker Ergun

Elcin Barker Ergun is a business leader in the pharmaceutical industry.[1] In September 2019 she was appointed chief executive officer and member of the board of directors of the Italian company Menarini Group.[2][3][4]

Biography

edit

Ergun graduated from TED Ankara College (high school) in Turkey, where she also played basketball and handball and was a member of the team that won the national championship three times. Elcin has a Bachelor of Science degree in computer engineering from Middle East Technical University in Ankara and an MBA from INSEAD (Institut Europeen d’Administration Des Affaires).[5]

Ergun's career started as a software engineer, working for five years in IT management in Amsterdam for ITT Corporation.[6] After her MBA in France, Ergun moved to the UK, leading marketing and supply chain projects at the Northern European head office of Honeywell[6] and later continued as subsidiary chief financial officer.[6] Ergun entered the pharmaceutical industry as chief financial officer of the Turkish subsidiary of GlaxoSmithKline.[7]

After joining Merck KGaA's Healthcare business,[2][5][7] Elcin took on roles of increasing seniority within the organisation becoming Executive Vice President and Head of Global Commercial for Merck Serono,[6] achieving significant leadership and business transformation across global commercial operations.[6] This followed her role as Senior Vice President and Head of Intercontinental Region, across the Middle East, Africa, and Russia/CIS countries.

Before she joined Menarini Group, Elcin was based in Boston[5][8] for three years as Executive Vice President,[5] Head of New Businesses[5][8] at Merck Healthcare.[9]

Under Ergun's leadership, Menarini has accomplished milestones such as the 2020 acquisition of Stemline Therapeutics,[10] a U.S. commercial-stage biopharmaceutical company,[11] formerly a public listed organization quoted on NASDAQ,[10] focused on the development and commercialization of novel oncology therapeutics.[10][11] As of 2025, the portfolio of Menarini Stemline, a wholly owned subsidiary of the Menarini Group, includes 3 oncology and onco-hematology products. [12][13][14][15]

In December 2023, the Menarini Group signed an exclusive licensing agreement with Insilico Medicine, a biotech company specializing in generative AI. The partnership grants Menarini global rights to develop and commercialize a small molecule inhibitor of KAT6, aimed at treating hormone-sensitive tumors and other potential therapeutic areas. [16] In December 2024, the Menarini Group and Insilico Medicine concluded a second exclusive licensing agreement. This partnership grants the Menarini Group global rights to develop and commercialize a preclinical molecule targeting an oncological area with a significant need for innovative therapeutic solutions. [17]

References

edit
  1. ↑ "Revitalizing Purpose: Q&A with Elcin Barker Ergun | Thought Leadership". Russell Reynolds Associates. Retrieved 2021-07-18.
  2. 1 2 "Menarini: Elcin Barker Ergun amministratore delegato Gruppo". 12 September 2019.
  3. ↑ "Elcin Barker Ergun, A Menarini Indus Farmaceutiche: Profile and Biography". Bloomberg News.
  4. ↑ "Menarini appoints new chief executive". thepharmaletter.com. Retrieved 2021-07-18.
  5. 1 2 3 4 5 marchitto (2020-12-14). "Menarini: Elcin Barker Ergun Group CEO". Adnkronos. Retrieved 2021-04-22.
  6. 1 2 3 4 5 "Keynote speaker - Elcin Ergun | HBA". hbanet.org. Retrieved 2021-04-22.
  7. 1 2 AG, BIOCOM. "Elcin Barker Ergun becomes Menarini CEO". european-biotechnology.com. Retrieved 2021-04-22.
  8. 1 2 Volonté, Chiara (2019-09-16). "Menarini: la via all'internazionalizzazione è donna". Industria Italiana (in Italian). Retrieved 2021-08-31.
  9. ↑ "Vibrant Science & Technology - EMD Group". merckgroup.com. Retrieved 2021-08-31.
  10. 1 2 3 "Menarini Group Completes Acquisition of Stemline Therapeutics - ANSA.it". ansa.it. Retrieved 2021-08-31.
  11. 1 2 "About Us". Stemline Therapeutics. Retrieved 2021-08-31.
  12. ↑ "Oncologia, farmaco Menarini approvato negli Stati Uniti". La Nazione. 3 February 2023. Retrieved 25 March 2026.
  13. ↑ "Neoplasia a cellule dendritiche plasmacitoidi blastiche, approvazione europea per tagraxofusp". Osservatorio Malattie Rare. 2 February 2021. Retrieved 25 March 2026.
  14. ↑ Fabrizia Maselli (2024-10-03). "Aifa approva selinexor di Menarini Stemline Italia per il mieloma multiplo". Milano Finanza. Retrieved 25 March 2026.
  15. ↑ Marco Landucci (21 December 2021). "Gruppo Menarini e Karyopharm Therapeutics: accordo per la commercializzazione di Nexpovio (selinexor)". Daily Health Industry. Retrieved 25 March 2026.
  16. ↑ "Menarini, accordo con Insilico per inibitore KAT6 del carcinoma mammario". Daily Health Industry. 8 January 2024. Retrieved 25 March 2026.
  17. ↑ "Menarini Group Licenses Preclinical Oncology Asset from Insilico Medicine". Contract Pharma. 10 January 2025. Retrieved 25 March 2026.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Elcin_Barker_Ergun&oldid=1345292703"